Milurit (Allopurinol)

Allopurinol is converted in the body to oxypurinol, a potent inhibitor of the enzyme xanthine oxidase. By blocking this enzyme, the conversion of hypoxanthine and xanthine to uric acid is reduced, leading to lower serum urate concentrations and decreased crystal formation.

The dosage of Milurit is individualized by the prescribing clinician based on the patient’s renal function, uric acid levels, and therapeutic goals. Physicians determine the appropriate strength and frequency, and patients should follow the prescribed regimen exactly.

Allopurinol’s pregnancy category is not definitively established. Use is generally reserved for situations where the potential benefit outweighs possible risks. Breastfeeding mothers should discuss potential exposure with their healthcare provider, as the drug can be excreted in milk.

To request Milurit, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

The primary alternative to allopurinol is febuxostat, another xanthine oxidase inhibitor. Allopurinol has a longer market history and is generally less expensive, while febuxostat may be preferred in patients with severe renal impairment because it is less dependent on renal clearance. Choice depends on individual patient factors and physician judgment.

Milurit should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture, heat, and direct sunlight. Do not store in bathrooms or near kitchen appliances that generate steam.

Milurit is taken orally, usually with a full glass of water. Tablets can be swallowed with or without food, but consistent administration with respect to meals helps maintain stable drug levels. Patients should not crush or chew the tablets unless specifically instructed by a healthcare professional.

Serious adverse events include severe hypersensitivity reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, agranulocytosis, acute interstitial nephritis, and hepatotoxicity. Any signs of rash, fever, sore throat, jaundice, or unexplained fatigue should prompt immediate medical evaluation.

Milurit is contraindicated in patients with known hypersensitivity to allopurinol or oxypurinol. It should be used with caution in individuals with severe renal impairment, active liver disease, or a history of severe cutaneous adverse reactions. Pregnant or breastfeeding women should only use it when clearly indicated by a physician.